Healio

Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children

Please provide your email address to receive an email when new articles are posted on . HBV-infected children treated with combination PEG-INF a-2b/nucleos(t)ide analogues achieved higher HBsAg loss ...
Healio

Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV

Please provide your email address to receive an email when new articles are posted on . Adjusted analysis demonstrated no association between nucleos(t)ide analogue retreatment and HBsAg seroclearance ...
Nasdaq

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive ...
Medscape

Tobevibart Plus Elebsiran Tackles Hepatitis D

A combination treatment involving tobevibart and elebsiran significantly improved disease activity in adults with chronic ...
MarketWatch

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b ...

-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...